{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:39:19Z","timestamp":1793785159865,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Spinal muscular atrophy (SMA) is a rare neuromuscular disorder leading to early death in the majority of affected individuals without treatment. Recently, targeted treatment approaches including Onasemnogene Abeparvovec (OA) were introduced. This study describes the first real-world experience with OA in Switzerland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective observational case series study using data collected within the Swiss Registry for Neuromuscular Disorders from SMA patients treated with OA. Development of motor, bulbar and respiratory function, appearance of scoliosis, and safety data (platelet count, liver function, and cardiotoxicity) were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine individuals were treated with OA and followed for 383\u2009\u00b1\u2009126\u2009days: six SMA type 1 (of which two with nusinersen pretreatment), one SMA type 2, and two pre-symptomatic individuals. In SMA type 1, CHOP Intend score increased by 28.1 from a mean score of 20.5\u2009\u00b1\u20097.6 at baseline. At end of follow-up, 50% of SMA type 1 patients required nutritional support and 17% night-time ventilation; 67% developed scoliosis. The SMA type 2 patient and two pre-symptomatically treated individuals reached maximum CHOP Intend scores. No patient required adaptation of the concomitant prednisolone treatment, although transient decrease of platelet count and increase of transaminases were observed in all patients. Troponin-T was elevated prior to OA treatment in 100% and showed fluctuations in 57% thereafter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>OA is a potent treatment for SMA leading to significant motor function improvements. However, the need for respiratory and especially nutritional support as well as the development of scoliosis must be thoroughly evaluated in SMA type 1 patients even in the short term after OA treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03133-6","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:28:30Z","timestamp":1677738510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study"],"prefix":"10.1186","volume":"23","author":[{"given":"Georg M.","family":"Stettner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Hasselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tscherter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elea","family":"Galiart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"3133_CR1","unstructured":"Prior TW, Leach ME, Finanger E. Spinal muscular atrophy - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/20301526\/ (Accessed 25 June 2022)."},{"key":"3133_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33:831\u201346. https:\/\/doi.org\/10.1016\/j.ncl.2015.07.004.","journal-title":"Neurol Clin"},{"key":"3133_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355\u201368. https:\/\/doi.org\/10.1002\/ana.24864.","journal-title":"Ann Neurol"},{"key":"3133_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.braindev.2020.07.012","volume":"43","author":"SF Ou","year":"2021","unstructured":"Ou SF, Ho CS, Lee WT, Lin KL, Jones CC, Jong YJ. Natural history in spinal muscular atrophy type I in Taiwanese population: a longitudinal study. Brain and Development. 2021;43:127\u201334. https:\/\/doi.org\/10.1016\/j.braindev.2020.07.012.","journal-title":"Brain and Development"},{"key":"3133_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391. https:\/\/doi.org\/10.1002\/ana.25101.","journal-title":"Ann Neurol"},{"key":"3133_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000741.","journal-title":"Neurology"},{"key":"3133_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review. Orphanet J Rare Dis. 2017;12:124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3133_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"key":"3133_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;14:11\u201325. https:\/\/doi.org\/10.2147\/TACG.S239603.","journal-title":"Appl Clin Genet"},{"key":"3133_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28:208\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003.","journal-title":"Neuromuscul Disord"},{"key":"3133_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/nejmoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332. https:\/\/doi.org\/10.1056\/nejmoa1702752.","journal-title":"N Engl J Med"},{"key":"3133_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2102047.","journal-title":"N Engl J Med"},{"key":"3133_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21:42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7.","journal-title":"Lancet Neurol"},{"key":"3133_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/nejmoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335. https:\/\/doi.org\/10.1056\/nejmoa1710504.","journal-title":"N Engl J Med"},{"key":"3133_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","volume":"32","author":"A Tscherter","year":"2022","unstructured":"Tscherter A, R\u00fcsch CT, Baumann D, Enzmann C, Hasselmann O, Jacquier D, et al. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscul Disord. 2022;32:399\u2013409. https:\/\/doi.org\/10.1016\/j.nmd.2022.02.001.","journal-title":"Neuromuscul Disord"},{"key":"3133_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"key":"3133_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9.","journal-title":"Lancet Neurol"},{"key":"3133_CR18","doi-asserted-by":"publisher","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","DOI":"10.1038\/s41591-022-01866-4"},{"key":"3133_CR19","doi-asserted-by":"publisher","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","DOI":"10.1038\/s41591-022-01867-3"},{"key":"3133_CR20","doi-asserted-by":"publisher","unstructured":"McMillan HJ, Proud CM, Farrar MA, Alexander IE, Muntoni F, Servais L. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. Expert Opin Biol Ther. 2022:1\u201316. https:\/\/doi.org\/10.1080\/14712598.2022.2066471.","DOI":"10.1080\/14712598.2022.2066471"},{"key":"3133_CR21","doi-asserted-by":"publisher","unstructured":"Blair HA. Onasemnogene Abeparvovec: a review in spinal muscular atrophy. CNS Drugs. 2022. https:\/\/doi.org\/10.1007\/s40263-022-00941-1.","DOI":"10.1007\/s40263-022-00941-1"},{"key":"3133_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00115-020-00919-8","volume":"91","author":"A Ziegler","year":"2020","unstructured":"Ziegler A, Wilichowski E, Schara U, Hahn A, M\u00fcller-Felber W, Johannsen J, et al. Handlungsempfehlungen zur Gentherapie der spinalen Muskelatrophie mit Onasemnogene Abeparvovec \u2013 AVXS-101. Nervenarzt. 2020;91:518\u201329. https:\/\/doi.org\/10.1007\/s00115-020-00919-8.","journal-title":"Nervenarzt"},{"key":"3133_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/JND-200538","volume":"8","author":"V Hodgkinson","year":"2021","unstructured":"Hodgkinson V, Lounsberry J, M\u2019Dahoma S, Russell A, Jewett G, Benstead T, et al. The Canadian neuromuscular disease registry 2010\u20132019: a decade of facilitating clinical research Througha Nationwide, Pan-NeuromuscularDisease Registry. J Neuromuscul Dis. 2021;8:53\u201361. https:\/\/doi.org\/10.3233\/JND-200538.","journal-title":"J Neuromuscul Dis"},{"key":"3133_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1051\/medsci\/2021187","volume":"37","author":"M Lemoine","year":"2021","unstructured":"Lemoine M, Gomez M, Grimaldi L, Urtizberea JA, Quijano-Roy S. Le registre national SMA France : des r\u00e9sultats d\u00e9j\u00e0 encourageants. M\u00e9decine\/Sciences. 2021;37:25\u20139. https:\/\/doi.org\/10.1051\/medsci\/2021187.","journal-title":"M\u00e9decine\/Sciences"},{"key":"3133_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, K\u00f6nig K, Bernert G, Schachtrup K, Schara U, Schorling D, et al. SMArtCARE - a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14:18. https:\/\/doi.org\/10.1186\/s13023-019-0998-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3133_CR26","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","volume":"23","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, McDermott MP, Montes J, Martens WB, Flickinger J, Riley S, et al. Validation of the Children\u2019s Hospital of Philadelphia Infant Test of neuromuscular disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23:322\u20136. https:\/\/doi.org\/10.1097\/PEP.0b013e3182351f04.","journal-title":"Pediatr Phys Ther"},{"key":"3133_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The Children\u2019s Hospital of Philadelphia Infant Test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155\u201361. https:\/\/doi.org\/10.1016\/j.nmd.2009.11.014.","journal-title":"Neuromuscul Disord"},{"key":"3133_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","volume":"28","author":"R de Sanctis","year":"2018","unstructured":"de Sanctis R, Pane M, Coratti G, Palermo C, Leone D, Pera MC, et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul Disord. 2018;28:24\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2017.09.015.","journal-title":"Neuromuscul Disord"},{"key":"3133_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135:153\u201361. https:\/\/doi.org\/10.1016\/S0022-3476(99)70016-8.","journal-title":"J Pediatr"},{"key":"3133_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17:39. https:\/\/doi.org\/10.1186\/s12883-017-0790-9.","journal-title":"BMC Neurol"},{"key":"3133_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693\u20137. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009.","journal-title":"Neuromuscul Disord"},{"key":"3133_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor Progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155\u20139. https:\/\/doi.org\/10.1016\/S1090-3798(03)00060-6.","journal-title":"Eur J Paediatr Neurol"},{"key":"3133_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41434-021-00273-7","volume":"28","author":"HG Ali","year":"2021","unstructured":"Ali HG, Ibrahim K, Elsaid MF, Mohamed RB, Abeidah MIA, al Rawwas AO, et al. Gene therapy for spinal muscular atrophy: the Qatari experience. Gene Ther. 2021;28:676\u201380. https:\/\/doi.org\/10.1038\/s41434-021-00273-7.","journal-title":"Gene Ther"},{"key":"3133_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/acn3.51519","volume":"9","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Holland S, Kariyawasam D, Herbert K, Barclay P, Cairns A, et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9:339\u201350. https:\/\/doi.org\/10.1002\/acn3.51519.","journal-title":"Ann Clin Transl Neurol"},{"key":"3133_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2021.01.012","volume":"118","author":"SE Matesanz","year":"2021","unstructured":"Matesanz SE, Battista V, Flickinger J, Jones JN, Kichula EA. Clinical experience with gene therapy in older patients with spinal muscular atrophy. Pediatr Neurol. 2021;118:1\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.01.012.","journal-title":"Pediatr Neurol"},{"key":"3133_CR36","doi-asserted-by":"publisher","unstructured":"Waldrop MA, Karingada C, Storey MA, Powers B, Iammarino MA, Miller NF, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020:146. https:\/\/doi.org\/10.1542\/peds.2020-0729.","DOI":"10.1542\/peds.2020-0729"},{"key":"3133_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df C, Ziegler A, Becker L-L, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6:17\u201327. https:\/\/doi.org\/10.1016\/S2352-4642(21)00287-X.","journal-title":"Lancet Child Adolesc Health"},{"key":"3133_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JND-200593","volume":"8","author":"J Friese","year":"2021","unstructured":"Friese J, Geitmann S, Holzwarth D, M\u00fcller N, Sassen R, Baur U, et al. Safety monitoring of gene therapy for spinal muscular atrophy with Onasemnogene Abeparvovec \u2013a single Centre experience. J Neuromuscul Dis. 2021;8:209\u201316. https:\/\/doi.org\/10.3233\/JND-200593.","journal-title":"J Neuromuscul Dis"},{"key":"3133_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.braindev.2021.12.006","volume":"44","author":"S Lee","year":"2022","unstructured":"Lee S, Lee YJ, Kong J, Ryu HW, Shim YK, Han JY, et al. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy. Brain and Development. 2022;44:287\u201393. https:\/\/doi.org\/10.1016\/j.braindev.2021.12.006.","journal-title":"Brain and Development"},{"key":"3133_CR40","doi-asserted-by":"publisher","unstructured":"Bitetti I, Lanzara V, Margiotta G, Varone A. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther. 2022. https:\/\/doi.org\/10.1038\/s41434-022-00341-6.","DOI":"10.1038\/s41434-022-00341-6"},{"key":"3133_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.27034","volume":"62","author":"Y Harada","year":"2020","unstructured":"Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ, Napchan-Pomerantz G, et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62:550\u20134. https:\/\/doi.org\/10.1002\/mus.27034.","journal-title":"Muscle Nerve"},{"key":"3133_CR42","doi-asserted-by":"publisher","unstructured":"AlNaimi A, Hamad SG, Mohamed RBA, Ben-Omran T, Ibrahim K, Osman MFE, et al. A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy. Pediatr Pulmonol. 2023. https:\/\/doi.org\/10.1002\/ppul.26285.","DOI":"10.1002\/ppul.26285"},{"key":"3133_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.sleep.2022.11.006","volume":"101","author":"C Leon-Astudillo","year":"2023","unstructured":"Leon-Astudillo C, Wagner M, Salabarria SM, Lammers J, Berthy J, Zingariello CD, et al. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec. Sleep Med. 2023;101:234\u20137. https:\/\/doi.org\/10.1016\/j.sleep.2022.11.006.","journal-title":"Sleep Med"},{"key":"3133_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis A. Novartis confirms deaths of two patients treated with gene therapy Zolgensma. Hum Gene Ther. 2022;33:842\u20134. https:\/\/doi.org\/10.1089\/hum.2022.29216.bfs.","journal-title":"Hum Gene Ther"},{"key":"3133_CR45","first-page":"1057","volume":"59","author":"E Hahnen","year":"1996","unstructured":"Hahnen E, Sch\u00f6nling J, Rudnik-Sch\u00f6neborn S, Zerres K, Wirth B. Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease. Am J Hum Genet. 1996;59:1057\u201365.","journal-title":"Am J Hum Genet"},{"key":"3133_CR46","doi-asserted-by":"publisher","unstructured":"Wadman RI, Jansen MD, Stam M, Wijngaarde CA, Curial CAD, Medic J, et al. Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Commun. 2020:2. https:\/\/doi.org\/10.1093\/braincomms\/fcaa075.","DOI":"10.1093\/braincomms\/fcaa075"},{"key":"3133_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, Coratti G, de Sanctis R, Pera MC, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15:84. https:\/\/doi.org\/10.1186\/s13023-020-01356-1.","journal-title":"Orphanet J Rare Dis"},{"key":"3133_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","volume":"3","author":"SJ Kolb","year":"2016","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Baseline results of the neuro <scp>NEXT<\/scp> spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3:132\u201345. https:\/\/doi.org\/10.1002\/acn3.283.","journal-title":"Ann Clin Transl Neurol"},{"key":"3133_CR49","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Five-year extension results of the phase 1 START trial of Onasemnogene Abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272.","journal-title":"JAMA Neurol"},{"key":"3133_CR50","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fr\u00e9meaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6:4266\u201370. https:\/\/doi.org\/10.1182\/bloodadvances.2021006419.","journal-title":"Blood Adv"},{"key":"3133_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC de Vivo","year":"2019","unstructured":"de Vivo DC, Bertini E, Swoboda KJ, Hwu W-L, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03133-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03133-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03133-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:28:33Z","timestamp":1677738513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03133-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3133"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03133-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"26 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this study data collected within the Swiss registry for Neuromuscular Disorders (Swiss-Reg-NMD) was used. This registry is hosted at the Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland, since 2017 and was approved by the Cantonal Ethics Committee of Bern (20.06.2018, KEK Bern, 2018-00289). Parents provided written informed consent for the participation of their children in the Swiss-Reg-NMD. All methods were carried out in accordance with relevant guidelines and regulation. The research has been performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GMS served on advisory boards of AveXis, Biogen, Novartis Gene Therapies and Roche.OH served on advisory boards of Biogen and Novartis Gene Therapies; he received speaker\u2019s honoraria from Biogen. DJ served on advisory boards of AveXis, Biogen, Novartis Gene Therapies and Roche; he received speaker\u2019s honoraria from Biogen and Roche, and a research grant from AveXis, Biogen and Roche. AT is employee of the Swiss-Reg-NMD.EG has no conflict of interest to report. AK served on advisory boards of AveXis, Biogen, Novartis Gene Therapies, Roche, Sarepta and Pfizer; she received speaker\u2019s honoraria from Roche, Biogen, Pfizer and Novartis Gene Therapies.The Swiss-Reg-NMD is funded by \u2018Schweizerische Muskelgesellschaft\u2019, \u2018Association Suisse Romande Intervenant contre les Maladies neuro-Musculaires\u2019, \u2018Associazione Malattie Genetiche Rare Svizzera italiana\u2019, \u2018SMA Schweiz\u2019, \u2018Duchenne Schweiz\u2019 \u2018Schweizerische Stiftung f\u00fcr die Erforschung der Muskelkrankheiten\u2019 FSRMM; and receives unconditional and research grants from PTC Therapeutics lnternational, Sarepta International, Pfizer Switzerland, AveXis EU Limited, Roche Pharma Schweiz, Novartis Gene Therapies, and Biogen Switzerland AG. None of the funders was involved in the study design, data collection, analysis, interpretation of data or writing the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}